US Drug Approved For Treating HIV Infection In Infants

Table of contents:

US Drug Approved For Treating HIV Infection In Infants
US Drug Approved For Treating HIV Infection In Infants

Video: US Drug Approved For Treating HIV Infection In Infants

Отличия серверных жестких дисков от десктопных
Video: Second US HIV-positive baby cured by early treatment 2023, January
Anonim

US drug approved for treating HIV infection in infants

The US Food and Drug Administration (FDA) has approved a drug for the treatment of HIV in children aged four weeks and older with a weight of three kilograms.

US drug approved for treating HIV infection in infants
US drug approved for treating HIV infection in infants

Photo: CC0 Public Domain

Two forms of the drug have been approved: tableted Tivicay (dolutegravir) and Tivicay PD (dolutegravir) in the form of a dispersible tablet, that is, dissolving in the mouth. The drug was developed by ViiV Healthcare, a company specializing in the creation of drugs for the treatment of HIV infection. According to the company, dolutegravir is the first antiviral drug in the class of second-generation integrase inhibitors. Previously, dolutegravir was prescribed only for children over six years of age and weighing more than 30 kg.

Both forms of the drug were approved in a study that included HIV-infected infants, children, and adolescents aged 4 weeks to 18 years. The average age of patients is 2.5 years. After 24 weeks, 62% of patients taking Tivicay or Tivicay PD had undetectable viral load, after 48 weeks this number increased to 69%. In addition, most of the subjects had a fairly high level of CD4 cells - an indicator that determines the resistance of the immune system.

ViiV Healthcare experts emphasize that the widespread use of the new drug will increase the possibilities for treatment and reduction of viral load in patients with HIV of different ages. According to the company, at least 1.7 million children worldwide are living with HIV today, and most AIDS deaths occur within the first five years. In the near future, ViiV Healthcare will focus on making the dispersible form of the drug, which is very easy to use for the smallest patients, to be available worldwide, including in Africa.

As Yevgeny Voronin, the chief freelance specialist on diagnostics and treatment of HIV infection of the Ministry of Health of the Ministry of Health, said earlier during an online conference of RBC, children are the most vulnerable patients with HIV, since their disease progresses faster than adults, and there are half the drugs available for them. … That is why doctors pay much attention to timely diagnosis and treatment of pregnant women. According to Voronin, in 2000, less than half of HIV-infected women in the country were registered, which is why 20% of children of such women were born infected. Currently, the number of children infected by mothers is 1.5%.

“If a mother registers on time and takes therapy, transmission of HIV to the child is practically impossible,” the expert said.

Popular by topic